stoxline Quote Chart Rank Option Currency Glossary
Arcus Biosciences, Inc. (RCUS)
16.07  1.01 (6.71%)    12-01 16:00
Open: 14.95
High: 16.1
Volume: 774,075
Pre. Close: 15.06
Low: 14.38
Market Cap: 1,203(M)
Technical analysis
2023-12-01 4:22:18 PM
Short term     
Mid term     
Targets 6-month :  19.79 1-year :  23.12
Resists First :  16.95 Second :  19.79
Pivot price 14.27
Supports First :  14.47 Second :  12.94
MAs MA(5) :  14.78 MA(20) :  14.61
MA(100) :  17.93 MA(250) :  19.29
MACD MACD :  -0.3 Signal :  -0.6
%K %D K(14,3) :  69.1 D(3) :  49.5
RSI RSI(14): 58.8
52-week High :  35.5 Low :  12.94
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ RCUS ] has closed Bollinger Bands are 36.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 16.1 - 16.16 16.16 - 16.21
Low: 14.28 - 14.34 14.34 - 14.4
Close: 15.94 - 16.05 16.05 - 16.14
Company Description

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

Headline News

Mon, 27 Nov 2023
Arcus Biosciences Announces New Employment Inducement Grants - Yahoo Finance

Mon, 27 Nov 2023
From laggards to leaders: Small caps on the rise - The Globe and Mail

Sun, 12 Nov 2023
Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Just Trimmed Their ... - Yahoo Finance

Thu, 09 Nov 2023
Global Anal Cancer Market Size Expected to Reach $1.24 Billion In ... - PR Newswire

Wed, 08 Nov 2023
Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call ... - Yahoo Finance

Mon, 06 Nov 2023
Gilead and Arcus Announce New Data Showing Encouraging ... - Gilead Sciences

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 75 (M)
Shares Float 54 (M)
Held by Insiders 29.9 (%)
Held by Institutions 77.6 (%)
Shares Short 6,920 (K)
Shares Short P.Month 6,620 (K)
Stock Financials
EPS -4
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.94
Profit Margin -244.2 %
Operating Margin -250 %
Return on Assets (ttm) -15.7 %
Return on Equity (ttm) -48.1 %
Qtrly Rev. Growth -3 %
Gross Profit (p.s.) -2.36
Sales Per Share 1.6
EBITDA (p.s.) -4.24
Qtrly Earnings Growth 0 %
Operating Cash Flow -288 (M)
Levered Free Cash Flow -161 (M)
Stock Valuations
PE Ratio -4.02
PEG Ratio 0
Price to Book value 2.31
Price to Sales 10.01
Price to Cash Flow -4.18
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android